

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India  
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurbindo.com

(Rs. In lakhs)

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2016**

	Standalone					
	Quarter ended		Nine months ended			
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	
Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Refer note 2
<b>1 Income from operations</b>						
(a) Net sales/income from operations (including excise duty)	246,035	234,921	233,901	717,797	670,308	
(b) Other operating income	6,102	6,095	6,276	18,315	17,220	
<b>Total income from operations (net)</b>	<b>252,137</b>	<b>241,016</b>	<b>240,177</b>	<b>736,112</b>	<b>687,528</b>	
<b>2 Expenses</b>						
(a) Cost of material consumed	117,822	118,388	114,986	348,441	330,181	
(b) Purchase of stock-in-trade	248	254	273	621	476	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,314	(4,043)	(7,462)	3,080	(14,305)	
(d) Employee benefits expense	23,081	21,945	20,876	67,480	59,337	
(e) Depreciation and amortisation expense	7,114	7,125	6,721	21,279	19,589	
(f) Other expenses	46,234	45,163	42,645	137,094	127,584	
<b>Total expenses</b>	<b>195,813</b>	<b>188,832</b>	<b>178,039</b>	<b>577,995</b>	<b>522,862</b>	
<b>3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)</b>	<b>56,324</b>	<b>52,184</b>	<b>62,138</b>	<b>158,117</b>	<b>164,666</b>	
4 Other Income	203	323	171	1,505	2,945	
<b>5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)</b>	<b>56,527</b>	<b>52,507</b>	<b>62,309</b>	<b>159,622</b>	<b>167,611</b>	
6 Finance costs (refer note 7)	1,020	1,193	1,740	3,610	4,911	
7 Foreign exchange (Gain)/Loss (refer note 7)	(2,707)	(3,149)	(520)	(6,968)	2,424	
<b>8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)</b>	<b>58,214</b>	<b>54,463</b>	<b>61,089</b>	<b>162,980</b>	<b>160,276</b>	
9 Exceptional item	-	-	-	-	-	
<b>10 Profit/(Loss) from ordinary activities before tax (8-9)</b>	<b>58,214</b>	<b>54,463</b>	<b>61,089</b>	<b>162,980</b>	<b>160,276</b>	
11 Tax expense/(credit)	14,112	12,539	14,675	37,849	38,940	
<b>12 Net Profit/(Loss) for the period (10-11)</b>	<b>44,102</b>	<b>41,924</b>	<b>46,414</b>	<b>125,131</b>	<b>121,336</b>	
13 Other Comprehensive income	(253)	(302)	115	(591)	(108)	
<b>14 Total Comprehensive income (12+13)</b>	<b>43,849</b>	<b>41,622</b>	<b>46,529</b>	<b>124,540</b>	<b>121,228</b>	
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,852	5,852	5,840	5,852	5,840	
16 Earnings per share of Re.1/- each (not annualised)						
(a) Basic	7.53	7.16	8.00	21.38	20.78	
(a) Diluted	7.53	7.16	8.00	21.38	20.77	



**NOTES:**

- 1 The Company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is April 01, 2015 and accordingly, these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- 2 The above standalone financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on February 09, 2017. A limited review of the standalone results for the quarter and nine months ended December 31, 2016 have been carried out by the Statutory Auditors. The financial results and other financial information for the quarter and nine months ended December 31, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- 3 There is a possibility that these quarterly financial results may require adjustment before constituting the final Ind AS financial statements as of and for the year ending 31 March 2017 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 4 The reconciliation of Net profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	Quarter ended December 31, 2015	Nine months ended December 30, 2015
<b>Net profit under previous GAAP</b>	46,571	121,182
Difference in measurement of employee benefit expenses	(127)	163
Others	(30)	(9)
<b>Net profit for the period under Ind AS</b>	46,414	121,336

- 5 The Company's operates in only one segment viz. 'Pharmaceutical Products'.
- 6 Sales of standalone for the current quarter include exports Rs.204,719 Lakhs (December 31, 2015 Rs.197,345 lakhs).
- 7 Foreign exchange (gain)/loss for standalone results includes exchange difference of Rs.Nil lakhs, Rs. Nil lakhs and Rs. 2,064 lakhs for quarter ended December 31, 2016, September 30, 2016 and December 31, 2015 respectively and Rs.Nil lakhs, Rs.15,884 lakhs for the nine months ended December 31, 2016 and December 31, 2015 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- 8 The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.



By Order of the Board  
  
 N. Govindarajan  
 Managing Director



Place: Hyderabad  
 Date : February 09, 2017  
 www.aurobindo.com

**Limited Review Report****Review Report to  
The Board of Directors  
Aurobindo Pharma Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended December 31, 2016 and year to date from April 01, 2016 to December 31, 2016 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.


This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not audited or reviewed the accompanying standalone financial results and other financial information for the quarter and year to date period ended December 31, 2015, which have been presented solely based on the information compiled by Management.

**For S.R. BATLIBOI & ASSOCIATES LLP**  
**ICAI Firm registration number: 101049W/E300004**  
Chartered Accountants



**per Vikas Kumar Pansari**  
Partner  
Membership No.: 93649



Place: Hyderabad  
Date: February 09, 2017

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2016**

	Consolidated					
	Quarter ended		31.12.2015		Nine months ended	
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	Unaudited Refer note 3
	Unaudited	Unaudited	Unaudited Refer note 3	Unaudited	Unaudited	Unaudited Refer note 3
<b>1 Income from operations</b>	<b>384,447</b>	<b>371,358</b>	<b>344,218</b>	<b>1,126,266</b>	<b>1,003,588</b>	
(a) Net sales/income from operations (Including excise duty)						
(b) Other operating income	6,171	6,187	6,342	18,557	17,342	
<b>Total income from operations (net)</b>	<b>390,618</b>	<b>377,545</b>	<b>350,560</b>	<b>1,144,823</b>	<b>1,020,930</b>	
<b>2 Expenses</b>						
(a) Cost of material consumed	130,059	132,975	123,913	390,550	359,326	
(b) Purchase of stock-in-trade	44,362	35,829	37,693	121,085	103,695	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,450)	(10,326)	(6,524)	(18,490)	(9,401)	
(d) Employee benefits expense	44,564	42,658	40,159	130,430	113,581	
(e) Depreciation and amortisation expense	11,114	11,020	9,935	32,758	28,097	
(f) Other expenses	85,599	83,488	73,546	249,944	221,549	
<b>Total expenses</b>	<b>312,248</b>	<b>295,644</b>	<b>278,722</b>	<b>906,277</b>	<b>816,847</b>	
<b>3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)</b>	<b>78,370</b>	<b>81,901</b>	<b>71,838</b>	<b>238,546</b>	<b>204,083</b>	
4 Other Income	792	828	754	3,209	4,910	
<b>5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)</b>	<b>79,162</b>	<b>82,729</b>	<b>72,592</b>	<b>241,755</b>	<b>208,993</b>	
6 Finance costs (refer note 7)	1,426	1,754	2,270	5,244	6,758	
7 Foreign exchange (Gain)/Loss (refer note 7)	(1,580)	(2,019)	(1,399)	(4,302)	4,051	
<b>8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)</b>	<b>79,316</b>	<b>82,994</b>	<b>71,721</b>	<b>240,813</b>	<b>198,184</b>	
9 Exceptional item	-	-	-	-	-	
<b>10 Profit / (Loss) from ordinary activities before tax (8-9)</b>	<b>79,316</b>	<b>82,994</b>	<b>71,721</b>	<b>240,813</b>	<b>198,184</b>	
11 Tax expense/(credit)	21,767	22,399	17,422	64,250	51,435	
<b>12 Net Profit / (Loss) for the period (10-11)</b>	<b>57,549</b>	<b>60,595</b>	<b>54,299</b>	<b>176,563</b>	<b>146,749</b>	
13 Share of ( loss)/profit of joint ventures	301	(40)	168	334	158	
14 Minority Interest	(9)	(9)	36	(24)	(124)	
<b>15 Net Profit/(Loss) after taxes, minority interest and share of loss/profit of joint ventures</b>	<b>57,859</b>	<b>60,564</b>	<b>54,431</b>	<b>176,921</b>	<b>147,031</b>	
16 Other Comprehensive income	(281)	(302)	115	(619)	(108)	
<b>17 Total Comprehensive income</b>	<b>57,578</b>	<b>60,262</b>	<b>54,546</b>	<b>176,302</b>	<b>146,923</b>	
18 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,852	5,852	5,840	5,852	5,840	
19 Earnings per share of Re.1/- each (not annualised)						
(a) Basic	9.88	10.41	9.32	30.23	25.18	
(a) Diluted	9.88	10.40	9.31	30.23	25.16	



28

**NOTES:**

- 1 These consolidated unaudited financial results relate to Aurobindo Pharma Limited ('the Holding Company'), its Subsidiaries (together constitute 'the Group') and Joint Ventures and are prepared by applying Ind AS 110 - "Consolidated Financial Statements" and Ind AS 28 - "Investments in Associates and Joint ventures".
- 2 The Group and joint ventures have adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is April 01, 2015 and accordingly, these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on February 09, 2017. A limited review of the consolidated financial results for the quarter and nine months ended December 31, 2016 have been carried out by the Statutory Auditors. The financial results and other financial information for the quarter and nine months ended December 31, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- 4 There is a possibility that these quarterly financial results may require adjustment before constituting the final Ind AS financial statements as of and for the year ending 31 March 2017 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 5 The reconciliation of Net profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	Quarter ended December 31, 2015	Nine months ended December 31, 2015
Net profit under previous GAAP	53,495	141,915
Impact on deferred tax (including on unrealised intragroup profits on inventories)	1,023	1,865
Impact of foreign currency exchange differences	(11)	2,866
Difference in measurement of employee benefit expenses	(126)	163
Other Ind AS adjustments	50	222
<b>Net profit for the period under Ind AS</b>	<b>54,431</b>	<b>147,031</b>

- 6 The Group has only one reportable segment namely 'Pharmaceuticals'.
- 7 Foreign exchange (gain)/loss for standalone results includes exchange difference of Rs.Nil lakhs, Rs. Nil lakhs and Rs. 2,064 lakhs for quarter ended December 31, 2016, September 30, 2016 and December 31, 2015 respectively and Rs.Nil lakhs, Rs.15,884 lakhs for the nine months ended December 31, 2016 and December 31, 2015 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- 8 The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.

Place: Hyderabad

Date : February 09, 2017

www.aurobindo.com



By Order of the Board

N.Govindarajan


Managing Director



**Limited Review Report****Review Report to  
The Board of Directors  
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Aurobindo Pharma Limited Group comprising Aurobindo Pharma Limited ('the Company') and its subsidiaries (together, 'the Group'), and joint ventures, for the quarter ended December 31, 2016 and year to date from April 01, 2016 to December 31, 2016 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review revenues of Rs. 183,487 lakhs and Rs. 548,285 lakhs for the quarter and year to date period ended December 31, 2016 respectively, included in the accompanying unaudited consolidated financial results relating to subsidiaries, whose financial information have been reviewed by the other auditors and whose reports have been furnished to us. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiaries is based solely on the reports of the other auditors.
4. Based on our review conducted as above and on consideration of reports of other auditors on the unaudited separate quarterly financial results and on the other financial information of the components, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We have not audited or reviewed the accompanying consolidated financial results and other financial information for the quarter and year to date period ended December 31, 2015, which have been presented solely based on the information compiled by Management.

**For S.R. BATLIBOI & ASSOCIATES LLP**  
**ICAI Firm registration number: 101049W/E300004**  
Chartered Accountants



**per Vikas Kumar Pansari**  
Partner  
Membership No.: 93649



Place: Hyderabad  
Date: February 09, 2017